493 related articles for article (PubMed ID: 32299391)
1. Treatment-related changes in neuroendocrine tumors as assessed by textural features derived from
Weber M; Kessler L; Schaarschmidt B; Fendler WP; Lahner H; Antoch G; Umutlu L; Herrmann K; Rischpler C
BMC Cancer; 2020 Apr; 20(1):326. PubMed ID: 32299391
[TBL] [Abstract][Full Text] [Related]
2. Textural analysis of hybrid DOTATOC-PET/MRI and its association with histological grading in patients with liver metastases from neuroendocrine tumors.
Weber M; Kessler L; Schaarschmidt B; Fendler WP; Lahner H; Antoch G; Umutlu L; Herrmann K; Rischpler C
Nucl Med Commun; 2020 Apr; 41(4):363-369. PubMed ID: 31977752
[TBL] [Abstract][Full Text] [Related]
3. Multimodal imaging for early functional response assessment of (90)Y-/ (177)Lu-DOTATOC peptide receptor targeted radiotherapy with DW-MRI and (68)Ga-DOTATOC-PET/CT.
Wulfert S; Kratochwil C; Choyke PL; Afshar-Oromieh A; Mier W; Kauczor HU; Schenk JP; Haberkorn U; Giesel FL
Mol Imaging Biol; 2014 Aug; 16(4):586-94. PubMed ID: 24526358
[TBL] [Abstract][Full Text] [Related]
4. Peptide receptor radionuclide therapy of neuroendocrine tumors with (90)Y-DOTATOC: is treatment response predictable by pre-therapeutic uptake of (68)Ga-DOTATOC?
Öksüz MÖ; Winter L; Pfannenberg C; Reischl G; Müssig K; Bares R; Dittmann H
Diagn Interv Imaging; 2014 Mar; 95(3):289-300. PubMed ID: 24034971
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of
Sawicki LM; Deuschl C; Beiderwellen K; Ruhlmann V; Poeppel TD; Heusch P; Lahner H; Führer D; Bockisch A; Herrmann K; Forsting M; Antoch G; Umutlu L
Eur Radiol; 2017 Oct; 27(10):4091-4099. PubMed ID: 28439648
[TBL] [Abstract][Full Text] [Related]
6.
Mapelli P; Bezzi C; Palumbo D; Canevari C; Ghezzo S; Samanes Gajate AM; Catalfamo B; Messina A; Presotto L; Guarnaccia A; Bettinardi V; Muffatti F; Andreasi V; Schiavo Lena M; Gianolli L; Partelli S; Falconi M; Scifo P; De Cobelli F; Picchio M
Eur J Nucl Med Mol Imaging; 2022 Jun; 49(7):2352-2363. PubMed ID: 35156146
[TBL] [Abstract][Full Text] [Related]
7. Differential uptake of (68)Ga-DOTATOC and (68)Ga-DOTATATE in PET/CT of gastroenteropancreatic neuroendocrine tumors.
Poeppel TD; Binse I; Petersenn S; Lahner H; Schott M; Antoch G; Brandau W; Bockisch A; Boy C
Recent Results Cancer Res; 2013; 194():353-71. PubMed ID: 22918768
[TBL] [Abstract][Full Text] [Related]
8. Differentiated thyroid cancer: a new perspective with radiolabeled somatostatin analogues for imaging and treatment of patients.
Versari A; Sollini M; Frasoldati A; Fraternali A; Filice A; Froio A; Asti M; Fioroni F; Cremonini N; Putzer D; Erba PA
Thyroid; 2014 Apr; 24(4):715-26. PubMed ID: 24102584
[TBL] [Abstract][Full Text] [Related]
9. SUV of [68Ga]DOTATOC-PET/CT Predicts Response Probability of PRRT in Neuroendocrine Tumors.
Kratochwil C; Stefanova M; Mavriopoulou E; Holland-Letz T; Dimitrakopoulou-Strauss A; Afshar-Oromieh A; Mier W; Haberkorn U; Giesel FL
Mol Imaging Biol; 2015 Jun; 17(3):313-8. PubMed ID: 25319765
[TBL] [Abstract][Full Text] [Related]
10. Quantitative 3D Assessment of
Adams LC; Bressem KK; Brangsch J; Reimann C; Nowak K; Brenner W; Makowski MR
J Nucl Med; 2020 Jul; 61(7):1021-1027. PubMed ID: 31862798
[No Abstract] [Full Text] [Related]
11. 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors.
Poeppel TD; Binse I; Petersenn S; Lahner H; Schott M; Antoch G; Brandau W; Bockisch A; Boy C
J Nucl Med; 2011 Dec; 52(12):1864-70. PubMed ID: 22072704
[TBL] [Abstract][Full Text] [Related]
12. Somatostatin receptor subtype expression and radiomics from DWI-MRI represent SUV of [68Ga]Ga-DOTATOC PET in patients with meningioma.
Iglseder S; Iglseder A; Beliveau V; Heugenhauser J; Gizewski ER; Kerschbaumer J; Stockhammer G; Uprimny C; Virgolini I; Dudas J; Nevinny-Stickel M; Nowosielski M; Scherfler C
J Neurooncol; 2023 Sep; 164(3):711-720. PubMed ID: 37707754
[TBL] [Abstract][Full Text] [Related]
13. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification.
Velikyan I; Sundin A; Sörensen J; Lubberink M; Sandström M; Garske-Román U; Lundqvist H; Granberg D; Eriksson B
J Nucl Med; 2014 Feb; 55(2):204-10. PubMed ID: 24379222
[TBL] [Abstract][Full Text] [Related]
14. Dynamic 68Ga-DOTATOC PET/CT and static image in NET patients. Correlation of parameters during PRRT.
Van Binnebeek S; Koole M; Terwinghe C; Baete K; Vanbilloen B; Haustermans K; Clement PM; Bogaerts K; Verbruggen A; Nackaerts K; Van Cutsem E; Verslype C; Mottaghy FM; Deroose CM
Nuklearmedizin; 2016 Jun; 55(3):104-14. PubMed ID: 27056060
[TBL] [Abstract][Full Text] [Related]
15. Additional information gained by positron emission tomography with (68)Ga-DOTATOC for suspected unknown primary or recurrent neuroendocrine tumors.
Nakamoto Y; Sano K; Ishimori T; Ueda M; Temma T; Saji H; Togashi K
Ann Nucl Med; 2015 Jul; 29(6):512-8. PubMed ID: 25894056
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Value of
Zhang J; Liu Q; Singh A; Schuchardt C; Kulkarni HR; Baum RP
J Nucl Med; 2020 Nov; 61(11):1560-1569. PubMed ID: 32169914
[TBL] [Abstract][Full Text] [Related]
17. Early Prediction of Treatment Response of Neuroendocrine Hepatic Metastases after Peptide Receptor Radionuclide Therapy with
Weikert T; Maas OC; Haas T; Klarhöfer M; Bremerich J; Forrer F; Sauter AW; Sommer G
Contrast Media Mol Imaging; 2019; 2019():1517208. PubMed ID: 31787860
[TBL] [Abstract][Full Text] [Related]
18. Potential value of pre- and post-therapy [68Ga]Ga-DOTA-TATE PET/CT in the prognosis of response to PRRT in disseminated neuroendocrine tumors.
Opalińska M; Morawiec-Sławek K; Kania-Kuc A; Al Maraih I; Sowa-Staszczak A; Hubalewska-Dydejczyk A
Front Endocrinol (Lausanne); 2022; 13():929391. PubMed ID: 36046793
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous 68Ga-DOTATOC PET/MRI in patients with gastroenteropancreatic neuroendocrine tumors: initial results.
Beiderwellen KJ; Poeppel TD; Hartung-Knemeyer V; Buchbender C; Kuehl H; Bockisch A; Lauenstein TC
Invest Radiol; 2013 May; 48(5):273-9. PubMed ID: 23493121
[TBL] [Abstract][Full Text] [Related]
20. Prediction of
Mileva M; Marin G; Levillain H; Artigas C; Van Bogaert C; Marin C; Danieli R; Deleporte A; Picchia S; Stathopoulos K; Jungels C; Vanderlinden B; Paesmans M; Ameye L; Critchi G; Taraji-Schiltz L; Velghe C; Wimana Z; Bali M; Hendlisz A; Flamen P; Karfis I
J Nucl Med; 2024 Feb; 65(2):236-244. PubMed ID: 38164576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]